Receiver appointed for insolvent Hyal

Article Abstract:

Hyal Pharmaceutical Corp has been placed under receivership following its acknowledgement that it failed to repay C$750,000 of debt that was due. The company's biggest creditor SkyePharma PLC of the UK has acquired to acquire 100% of of Hyal's secured debt of nearly C$1 million and 83% of the $5.2-million unsecured debt. SkyePharma would also acquire Hyal's drug delivery technology and its flagship Solarase product for treating sunspots. PricewaterhouseCoopers has been appointed as reciever of the insolvent biotech firm.

Canada, Pharmaceutical Preparation Manufacturing, Pharmaceutical Preparations, Drugs, Hyal Pharmaceutical Corp.

---

New Lorus drug shows promising results: Company enters final leg of clinical study for pancreatic cancer treatment Virulizin

Article Abstract:

Lois Walter a 78-year-old lady from Mapleton, Iowa, was diagnosed with pancreatic cancer, which is one of the deadliest disease. Mrs. Walter is taking an experimental drug called Virulizin which represents a potential break through in the treatment of pancreatic cancer has helped her to lead a life without much pain.

Product development, Iowa, Health aspects, Care and treatment, Usage, Diagnosis, Pancreatic cancer, Virulizin (Medication)

---

Sale of Patheon one step closer after company hires advisers

Article Abstract:

Sign up of investment advisers by Patheon Inc., to evaluate strategic and financial alternatives with relation to its plans of sale is presented.

Management dynamics, Management, Company restructuring/company reorganization, Reorganization and restructuring, Company business management, Financial analysts, Company organization, Patheon Inc.

Similar abstracts:

• Abstracts: Russia and the former Soviet Republics. Electing the president: Should presidential campaigns be financed by public funds?
• Abstracts: Efficacy of smoking cessation intervention among special populations: Review of the literature from 2000 to 2005
• Abstracts: Quantifying smoking cessation outcomes: The Women's Initiative for Nonsmoking Study (X): Methodological implications. part 2
• Abstracts: Turmoil at Alberta regulator muddies the waters. Good times a bad time to change royalties. Europe walks the talk on oil use
• Abstracts: Another WestJet veteran executive calls it quits. WestJet hires a new CFO after lengthy search. Beddoe makes move (again) in WestJet succession plan

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.